The Association of Periconception Asthma Medication Discontinuation with Adverse Obstetric Outcomes
American Journal of Perinatology · 01.05.2024 · 41 (S 01 S 01) · e2089-e2097
DOI: 10.1055/a-2097-1468 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.05.2024. Verfasst von Matthew C H Rohn und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institut…. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Pregnancy Complications. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, University of Alabama at Birmingham, and the Emmes Company for the Data Coordinating Center, National Institutes of Health Intramural Research Program at the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Objective
This study aimed to investigate asthma medication reduction in the periconceptional period as it relates to asthma status and adverse outcomes in pregnancy. Study Design In a prospective cohort study, self-reported current and past asthma medications were collected and analyzes compared measures of asthma status in women who discontinued asthma medication in the 6 months prior to enrollment (“step-down”) versus those who did not (“no change”). Evaluation of asthma was done at three study visits (one per trimester) and by daily diaries, including measures of lung function (percent predicted forced expiratory volume in 1 and 6 s [%FEV1, %FEV6], peak expiratory flow [%PEF], forced vital capacity [%FVC], FEV1 to FVC ratio [FEV1/FVC]), lung inflammation (fractional exhaled nitric oxide [FeNO], ppb), rate of asthma symptoms (activity limitation, night symptoms, rescue inhaler use, wheeze, shortness of breath, cough, chest tightness, chest pain), and rate of asthma exacerbations. Adverse pregnancy outcomes were also evaluated. Adjusted regression analyses examined whether adverse outcomes differed by periconceptional asthma medication changes.
Results
Of 279 participants included in analyses, 135 (48.4%) did not change asthma medication in the periconceptional period, whereas 144 (51.6%) reported a step down in medication. Those in the step-down group were more likely to have milder disease (88 [61.1%] in the step-down vs. 74 [54.8%] in the no change group), exhibited less activity limitation (rate ratio [RR]: 0.68, 95% confidence interval [CI]: 0.47–0.98), and experienced fewer asthma attacks (RR: 0.53, 95% CI: 0.34–0.84) during pregnancy. The step-down group had a nonsignificant increase in overall odds of experiencing an adverse pregnancy outcome (odds ratio: 1.62, 95% CI: 0.97–2.72).
Conclusion
Over half of women with asthma reduce asthma medication in the periconceptional period. Although these women typically have milder disease, a step down in medication may be associated with an increased risk of adverse pregnancy outcomes. Key Points
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
- Department of Obstetrics and Gynecology, George Washington University Hospital, Washington, District of Columbia.
- Northwestern University Feinberg School of Medicine, Chicago, Illinois.
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
- The University of Alabama at Birmingham, Birmingham, Alabama.
- Ochsner Health, New Orleans, Louisiana.
ORCID-Profile: Matthew C H Rohn
Förderung
- NICHD NIH HHS
- University of Alabama at Birmingham, and the Emmes Company for the Data Coordinating Center
- National Institutes of Health Intramural Research Program at the Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Northwestern University
Zitieren
APA
Rohn, M. C. H., Stevens, D. R., Grobman, W. A., Kumar, R., Chen, Z., Deshane, J., Biggio, J. R., Subramaniam, A., Grantz, K. L., Sherman, S., & Mendola, P. (2024). The Association of Periconception Asthma Medication Discontinuation with Adverse Obstetric Outcomes. American Journal of Perinatology, 41(S 01 S 01), e2089-e2097. https://doi.org/10.1055/a-2097-1468
Vancouver
Rohn MCH, Stevens DR, Grobman WA, Kumar R, Chen Z, Deshane J, et al. The Association of Periconception Asthma Medication Discontinuation with Adverse Obstetric Outcomes. American Journal of Perinatology. 2024;41(S 01 S 01):e2089-e2097. doi:10.1055/a-2097-1468
BibTeX
@article{Rohn2024,
author = {Rohn, Matthew C H and Stevens, Danielle R and Grobman, William A and Kumar, Rajesh and Chen, Zhen and Deshane, Jessy and Biggio, Joseph R and Subramaniam, Akila and Grantz, Katherine L and Sherman, Seth and Mendola, Pauline},
title = {The Association of Periconception Asthma Medication Discontinuation with Adverse Obstetric Outcomes},
journal = {American Journal of Perinatology},
year = {2024},
volume = {41},
number = {S 01 S 01},
pages = {e2089--e2097},
doi = {10.1055/a-2097-1468}
}
EUVIMED